Meta-analysis · 2019
Efficacy and safety of sertraline for the treatment of premature ejaculation: Systematic review and meta-analysis
Yi ZM, Chen SD, Tang QY, Tang HL, Zhai SD (2019). Efficacy and safety of sertraline for the treatment of premature ejaculation: Systematic review and meta-analysis. Medicine (Baltimore). doi:10.1097/MD.0000000000015989
Pooling 14 randomised trials (977 men), sertraline lengthened latency and improved the sexual satisfaction of both men and their partners compared with controls, but raised the risk of stomach upset about 2.7-fold.
Summary
Sertraline is a selective serotonin reuptake inhibitor (SSRI) antidepressant that doctors prescribe off-label for premature ejaculation (PE). This review searched Medline, Embase, the Cochrane Library and two Chinese databases for randomised controlled trials and randomised crossover trials of sertraline in men with PE.
Twelve randomised controlled trials and two crossover trials (977 men in total) were included. Sertraline prolonged intravaginal ejaculatory latency time (IELT: the time from penetration to ejaculation), with a standardised mean difference of 2.14 (95% CI 1.20 to 3.08), and the effect was present at 4, 6 and 8 weeks of treatment. Sexual satisfaction rates improved for the men and for their spouses. The risk of gastrointestinal upset was higher with sertraline (risk ratio 2.71, 95% CI 1.39 to 5.28).
Limitations
The result is a standardised effect size, so it does not translate directly into minutes. The included trials varied in dose, schedule (daily or on demand), comparison group and length, and many were small. Follow-up was short, so the review says nothing about what happens after stopping.
What it means for you
Sertraline does delay ejaculation on average, and in these trials partners' satisfaction improved too. The most consistent downside was stomach upset. It is a prescription medicine used off-label for PE, so the dose, schedule and how to stop are decisions to make with a doctor.